AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01907204
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide by nebulization
Trial: NCT03352206
Drug: 2 drug dose - DA
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
Trial: NCT03457129
Drug: Perampanel Oral Tablet
RxNorm normalized name: perampanel Oral Tablet
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
Trial: NCT03102021
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 units/kg daily for 3 days at onset of acute kidney injury
Trial: NCT03102021
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline 10 ml for 3 days
Trial: NCT00461682
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04065906
Drug: Methylphenidate or Tomoxetine
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
Trial: NCT03593408
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered for sedation management per hospital protocol
Trial: NCT01204164
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib per PI
Trial: NCT01204164
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Oral or IV)
Trial: NCT03593408
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered for sedation management per hospital protocol
Trial: NCT03593408
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered for sedation management per hospital protocol
Trial: NCT00556712
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg po daily
Trial: NCT00284934
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04568772
Drug: Atovaquone / Proguanil 250/100 mg
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone / Proguanil 250/100 mg tablet
Trial: NCT04568772
Drug: Tegoprazan 50 mg
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 50 mg tablet
Trial: NCT04568772
Drug: Esomeprazole 40 mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg tablet
Trial: NCT04568772
Drug: Vonoprazan 20 mg
RxNorm normalized name: vonoprazan 20 MG
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20 mg tablet
Trial: NCT03342859
Drug: Vilaprisan, BAY1002670
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
Trial: NCT03342859
Drug: Ulipristal
RxNorm normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily single oral doses of 5 mg ulipristal over 8-12 weeks
Trial: NCT01783782
Drug: polyethylene glycol 4000 solution with simethicon
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
Trial: NCT01783782
Drug: simethicon
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
Trial: NCT00326495
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
Trial: NCT02415803
Drug: low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg loading dose, then 45 mg twice daily for 5 days
Trial: NCT02415803
Drug: conventional-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg loading dose, then 90 mg twice daily for 5 days
Trial: NCT02415803
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg loading dose, then 75 mg once daily for 5 days
Trial: NCT00358579
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg
Trial: NCT00358579
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 IU
Trial: NCT01129284
Drug: ACTHAR gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
Trial: NCT00784927
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00784927
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00422461
Drug: PF-00489791
RxNorm normalized name: PF-00489791
DrugBank: PF-00489791 (DB11736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
Trial: NCT00422461
Drug: PF-00489791
RxNorm normalized name: PF-00489791
DrugBank: PF-00489791 (DB11736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00489791 4 mg, oral, tablets, once daily, for 28 days
Trial: NCT00422461
Drug: PF-00489791
RxNorm normalized name: PF-00489791
DrugBank: PF-00489791 (DB11736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00489791 10 mg, oral, tablets, once daily, for 28 days
Trial: NCT02493855
Drug: Ombitasvir/ABT-450/Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ombitasvir/ABT-450/ritonavir combination tablets
Trial: NCT02493855
Drug: Dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasabuvir tablets
Trial: NCT02493855
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin tablets
Trial: NCT03548415
Drug: IONIS-GHR-LRx
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS GHR-LRx administered subcutaneously.
Trial: NCT00170755
Drug: Darifenacin
RxNorm normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
Trial: NCT05125627
Drug: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
RxNorm normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Trial: NCT01259882
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
Trial: NCT01259882
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
Trial: NCT03087760
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent Pembrolizumab after proton reirradiation
Trial: NCT01259882
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
Trial: NCT00884598
Drug: cilengitide
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02243826
Drug: 50:50 mixture of nitrous oxide/oxygen
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03010865
Drug: Sodium Butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
Trial: NCT00559117
Drug: VB-111
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
Trial: NCT03142451
Drug: Vehicle foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Trial: NCT00574951
Drug: motesanib diphosphate
RxNorm normalized name: trisodium diphosphate
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00585169
Drug: Memantine Hydrochloride
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
Trial: NCT01404260
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
Trial: NCT01404260
Drug: Gemcitabine +Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
Trial: NCT02244528
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00337194
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00337194
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03188705
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Trial: NCT03188705
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
Trial: NCT02993341
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005940
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00005940
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT02920567
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
Trial: NCT00003812
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003812
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003812
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003812
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02104011
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00201773
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg orally once per day for 16 weeks.
Trial: NCT00281580
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily for two weeks
Trial: NCT00281580
Drug: Telmisartan 20 mg
RxNorm normalized name: telmisartan 20 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 20 mg once daily for eight weeks
Trial: NCT00281580
Drug: Telmisartan 40 mg
RxNorm normalized name: telmisartan 40 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 10 mg
RxNorm normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once daily for six weeks
Trial: NCT00281580
Drug: Telmisartan 80 mg
RxNorm normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5g once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5mg once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 2.5 mg
RxNorm normalized name: amlodipine 2.5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5 mg once daily for eight weeks
Trial: NCT00281580
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5g once daily for two weeks
Trial: NCT02520947
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: volatile agent for maintenance of anesthesia
Trial: NCT01694186
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00026403
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00026403
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005684
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02065804
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection, once, 5 min
Trial: NCT00671502
Drug: Carisoprodol SR
RxNorm normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 700 mg twice daily
Trial: NCT00671502
Drug: Carisoprodol SR
RxNorm normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily
Trial: NCT02662907
Drug: Barium
RxNorm normalized name: barium
DrugBank: Barium sulfate (DB11150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
Trial: NCT01168531
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin: 300 mg/day, po, from operative day until third postoperative day.
Trial: NCT01168531
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 16 mg, intravenous, before induction of anesthesia
Trial: NCT03162536
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
Trial: NCT00191152
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
Trial: NCT00191152
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression
Trial: NCT02358395
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily (800 mg total daily dose).
Trial: NCT00581789
Drug: erlotinib, sunitinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
Trial: NCT00806026
Drug: placebo and pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
Trial: NCT00806026
Drug: pramipexol
RxNorm normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Trial: NCT00806026
Drug: pramipexol
RxNorm normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.